Related references
Note: Only part of the references are listed.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments
Roland Haubner et al.
BIOMED RESEARCH INTERNATIONAL (2014)
RGD-based PET tracers for imaging receptor integrin αvβ3 expression
Hancheng Cai et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2013)
Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 Determined from Whole-Body PET/CT in Monkeys and Humans
Mohan Doss et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression
Peter A. Knetsch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
CURRENT CONCEPTS Hepatocellular Carcinoma
Hashem B. El-Serag
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Radio labelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system
Milos Petrik et al.
NUCLEAR MEDICINE COMMUNICATIONS (2011)
Positron emission tomography tracers for imaging angiogenesis
Roland Haubner et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients
Laura M. Kenny et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
[F-18]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates
R Haubner et al.
BIOCONJUGATE CHEMISTRY (2004)
Share Paper
